98%
921
2 minutes
20
Breast lymphomas, though rare, present a unique spectrum of clinical and pathological characteristics. This multicenter retrospective study evaluates 92 cases from four international institutions over a ten-year period to provide a comprehensive analysis of primary breast lymphomas (PBLs), secondary breast lymphomas (SBLs), and related subtypes, including breast implant-associated lymphomas (BIA-ALCL) and intra-mammary lymph node lymphomas. Primary breast lymphomas accounted for 46.7% of cases, with a predominance of diffuse large B-cell lymphoma (DLBCL). Secondary breast involvement, observed in 43.5% of cases, displayed a more diverse histological distribution, with follicular lymphoma being the most common subtype. Breast implant-associated lymphomas (BIA-ALCL) constituted 6.5% of cases, exclusively involving anaplastic large cell T-cell lymphoma, ALK-negative. The study highlights significant differences in patient demographics, clinical presentation, and survival outcomes. PBLs primarily affected older patients (mean age: 68.4 years) and were associated with longer lymphoma-specific survival compared to SBLs (76.12 vs. 59.45 months; p = 0.001). Notably, survival differences were evident within histological subtypes, emphasizing the impact of disease origin on prognosis. BIA-ALCL cases were distinct in clinical features and histology, with a younger mean age (47.5 years) and frequent association with unilateral effusion. This analysis underscores the necessity for precise diagnostic and therapeutic strategies tailored to the unique biology of breast lymphomas. Future research should aim to elucidate molecular mechanisms and optimize management protocols to improve patient outcomes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12334564 | PMC |
http://dx.doi.org/10.1038/s41598-025-13214-w | DOI Listing |
Mol Cancer Ther
September 2025
David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery and the Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.
Diffuse mesothelioma is a rare but highly aggressive and treatment-resistant neoplasm with low survival rates. Effective therapeutic strategies are limited, and resistance to treatment is a major obstacle. Myeloid cell leukemia (MCL)-1 and B-cell leukemia (BCL)-xL are antiapoptotic B-cell lymphoma 2 (Bcl-2) family proteins that block cell-intrinsic apoptosis through interactions on the mitochondrial outer membrane which contribute to therapeutic resistance.
View Article and Find Full Text PDFInt J Cancer
September 2025
Department of Public Health and AI, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Republic of Korea.
Population aging is an increasing challenge for cancer control in rapidly aging societies, yet remains inadequately quantified. We aim to project and illustrate the cancer burden attributable to aging in Korea by utilizing age-period-cohort (APC) models and population attributable fraction (PAF) concepts. From population-based cancer data, incidence and mortality of cancers primarily affected by aging (stomach, colorectal, liver, gallbladder, pancreatic, lung, non-Hodgkin lymphoma, esophagus, prostate, ovarian, male bladder cancers, and female leukemia) and breast cancer were extracted.
View Article and Find Full Text PDFInvest New Drugs
September 2025
Departamento de Química and Institute for Advanced Research in Chemical Science (IAdChem), Facultad de Ciencias, Universidad Autónoma de Madrid, Módulo 13, 28049, Madrid, Spain.
The oncogenic transcription factor MYC drives proliferation, metabolism, and therapy resistance in the majority of human cancers, yet its large, nuclear protein-protein interface has long frustrated direct drug discovery. A pivotal breakthrough was the identification of Tribbles pseudokinase 3 (TRIB3) as a high-affinity scaffold that binds the helix-loop-helix/leucine zipper region of MYC, blocks the E3-ubiquitin-ligase, UBE3B, from tagging critical lysines, and thereby prolongs MYC protein half-life while enhancing MYC-MAX transcriptional output. This review integrates structural, biochemical, and in vivo data to show how genetic deletion or pharmacological eviction of TRIB3 collapses MYC levels, silences its gene program, and suppresses tumor growth in B-cell lymphomas and selected solid tumors.
View Article and Find Full Text PDFJAMA Netw Open
September 2025
Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian, New York.
Importance: The incidence rate of primary breast anaplastic large cell lymphoma (ALCL), a complication associated with breast implants, is rapidly rising in the US. Comprehensive studies on the racial and ethnic epidemiologic characteristics of ALCL in the US are lacking, despite evidence of worldwide geographic variability.
Objective: To characterize the incidence rates of breast ALCL by race and ethnicity in the US.
Z Rheumatol
September 2025
Department of Rheumatology, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, 02841, Seoul, Korea (Republic of).
Objective: To evaluate standardized incidence ratios (SIRs) of cancer in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Methods: A systematic review and meta-analysis of studies from Medline, Embase, and Cochrane databases (inception to May 2025) was performed. Pooled SIRs were analyzed overall and by region, sex, age, AAV subtype, and cancer type.